AEON Biopharma, Inc. 8-K

What Happened
AEON Biopharma, Inc. filed an 8-K on April 3, 2026 disclosing that on March 31, 2026 it received a written notice from NYSE American that the company is not in compliance with Section 1003(a)(ii) of the NYSE American Company Guide. The notice follows AEON’s Form 10-K (filed March 30, 2026) which reported a stockholders’ deficit of approximately $55 million as of December 31, 2025 and net losses in three of the four most recent fiscal years.

Key Details

• NYSE standard at issue: Section 1003(a)(ii) requires at least $4.0 million in stockholders’ equity if a company has losses in 3 of 4 most recent fiscal years.
• AEON reported an approximate $55 million stockholders’ deficit as of 12/31/2025.
• AEON previously received an earlier non‑compliance notice (Original Notice) under Section 1003(a)(i) and submitted a compliance plan that was accepted in April 2025; the plan gives the company until August 3, 2026 to regain compliance.
• The new notice does not cause immediate delisting: AEON’s Class A common stock remains listed and will continue trading with a “.BC” indicator and inclusion on NYSE American’s noncompliant list. AEON retains the right to appeal any staff delisting decision.

Why It Matters
This notice formally notifies investors that AEON currently fails to meet NYSE American equity requirements, primarily due to a large stockholders’ deficit and multi‑year losses. While trading continues for now, failure to regain compliance by the plan deadline (August 3, 2026) could lead to delisting or additional shareholder‑level impacts. AEON says it will continue to execute its compliance plan but provides no assurance of success — investors should monitor future updates, the company’s financial results, and any NYSE actions.